BIoVector? UTI89 strain is a well-characterized, clinically isolated uropathogenic Escherichia coli (UPEC) used as a model organism in urinary tract infection (UTI) research. It was originally isolated from a patient with uncomplicated cystitis and has since been instrumental in studying the molecular mechanisms of UPEC virulence.

• Pathogenic origin: UTI89 is a clinical isolate from a human patient with acute bladder inflammation (cystitis). It belongs to phylogroup B2, a lineage of E. coli frequently associated with extraintestinal infections.

• Virulence factors: UTI89 is equipped with several genetic features that enhance its ability to cause infection, including:

  • Pathogenicity Islands (PAIs): It possesses four major PAIs, which are distinct from those in non-pathogenic E. coli strains and contain genes that contribute to its disease-causing potential.

  • Virulence plasmid (pUTI89): This large extrachromosomal plasmid contains virulence genes and plays a critical role during the initial stages of infection by promoting bladder colonization and invasion.

  • Adhesins: UTI89 has multiple pilus operons, including type 1 pili, which help it adhere to the urinary tract's epithelial cells. The FimH adhesin on the tip of type 1 pili is particularly important for this process.

  • Toxins: The strain produces several toxins, including hemolysin and cytotoxic necrotizing factor (CNF), that can damage host cells and aid infection.

  
  

• Infection cycle: In mouse models, UTI89 replicates within the bladder's urothelial cells, forming intracellular bacterial communities (IBCs). This provides a niche where the bacteria are protected from the host's immune response and antibiotics.

• UPEC fitness: Identifying the essential genes required for its survival and growth in different environments, including laboratory media, human urine, and the mouse bladder.

• Host-pathogen interactions: Understanding how the bacterium adapts to the host's immune response and manipulates host cell processes.

• Biofilm formation: Investigating the complex biofilm structures it creates at the air-liquid interface and how they protect the bacteria.

• Therapeutic development: Testing novel strategies to combat antibiotic-resistant UPEC, such as phage therapy.

• 

• 

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com

• 致病性來源： UTI89是從一名患有急性膀胱炎的患者身上分離出的臨床菌株。它屬于系統(tǒng)發(fā)育B2群，該譜系的大腸桿菌常與腸道外感染相關(guān)。

• 毒力因子： UTI89擁有多種增強(qiáng)其致病能力的遺傳特征，其中包括：

  • 致病島（PAIs）： 它擁有四個主要的致病島，這些致病島與非致病性大腸桿菌菌株不同，并包含有助于其致病潛力的基因。

  • 毒力質(zhì)粒（pUTI89）： 這個大型染色體外質(zhì)粒包含毒力基因，在感染的早期階段通過促進(jìn)膀胱定殖和侵襲而發(fā)揮關(guān)鍵作用。

  • 黏附素： UTI89擁有多個菌毛操縱子，包括1型菌毛，這有助于它黏附到尿路的表皮細(xì)胞上。1型菌毛頂端的FimH黏附素對此過程尤為重要。

  • 毒素： 該菌株產(chǎn)生多種毒素，包括溶血素和細(xì)胞毒性壞死因子（CNF），這些毒素可以破壞宿主細(xì)胞并幫助感染。

  
  

• 感染周期： 在小鼠模型中，UTI89在膀胱的尿路上皮細(xì)胞內(nèi)復(fù)制，形成細(xì)胞內(nèi)細(xì)菌群落（IBCs）。這為細(xì)菌提供了一個可以躲避宿主免疫反應(yīng)和抗生素的“庇護(hù)所”。

• UPEC適應(yīng)性： 識別其在不同環(huán)境（包括實(shí)驗(yàn)室培養(yǎng)基、人體尿液和小鼠膀胱）中生存和生長所必需的關(guān)鍵基因。

• 宿主-病原體相互作用： 理解細(xì)菌如何適應(yīng)宿主的免疫反應(yīng)并操控宿主細(xì)胞過程。

• 生物膜形成： 研究其在氣液界面形成的復(fù)雜生物膜結(jié)構(gòu)，以及這些結(jié)構(gòu)如何保護(hù)細(xì)菌。

• 治療方法開發(fā)： 測試對抗耐藥性UPEC的新策略，例如噬菌體療法。

• 
  

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com